用Heck反应合成1-羟基-4-(3-吡啶基)丁-2-酮

在Heck反应条件下,以Ph3P为催化剂配体,由3-卤代吡啶和3-丁烯-1,2-二醇进行偶合可以得到1-羟基-4-(3-吡啶基)丁-2-酮,具有原料易得、合成方法简单的优点.     

1-(2-氯-4-吡啶基)-3-苯基脲的合成

氯氨基吡啶;氯吡啶基苯基脲;1-(2-氯-4-吡啶基)-3-苯基脲的合成     

(2S,4S)-苯甲基-2-(6-氟-1H-吲哚-3-羰基)-4-羟基-吡咯烷-1-羧酸酯的合成

以4-羟基-L-脯氨酸为原料,经Cbz保护、偶联、Mitsunobu反应和水解合成了抗肿瘤新药Birinapant的重要中间体--(2S,4S)-苯甲基-2-(6-氟-1H-吲哚-3-羰基)-4-羟基吡咯烷-1-羧酸酯,总收率83%,其结构经¹H NMR和ESI-MS确证。     

3-(3＇-羟基丁基)异苯并呋喃-1(3H)-酮的合成

由邻苯二甲酸酐为原料,经中间体3-羟基苯酞(3),再经溴丙烯及锡存在下3的烯丙基化、硼氢化氧化、铬酐氧化、二甲基锌甲基化,共6步反应合成了3-(3＇-羟基丁基)异苯并呋喃-1(3H)-酮.     

4-(2-羧基苄氧基)苯乙酸的合成工艺改进

对羟基苯乙酸二钠盐与苯酞在N,N-二甲基乙酰胺中完成开环反应,合成了抗过敏药盐酸奥洛他定的重要中间体——4-(2-羧基苄氧基)苯乙酸,其结构经1H NMR确证,收率78%,纯度99%(HPLC)。     

新方法合成4-氰基-1-茚酮

以邻氰基氯苄和丙二酸二乙酯为原料,经缩合、碱水解、脱羧和Friedel-Crafts酰化反应合成了4-氰基-1-茚酮,总收率32.1%,其结构经1H NMR和13C NMR确证。     

普仑司特中间体8-氨基-4-氧代-2-(1H-四唑-5-基)-4H-1-苯并吡喃的合成

以3-氨基-2-羟基-苯乙酮为起始原料，经酰胺化、缩合、环合及脱保护反应合成了普仑司特关键中间体8-氨基-4-氧代-2-(1H-四唑-5-基)-4H-1-苯并吡喃，总收率40.1%，其结构经¹H NMR和MS确证。该路线中脱保护和环合两步反应采用了一锅法，并对合成工艺进行了优化。     

3-(3''''-羟基丁基)异苯并呋喃-1(3H)-酮的合成

由邻苯二甲酸酐为原料 ,经中间体 3 羟基苯酞 (3 ) ,再经溴丙烯及锡存在下 3的烯丙基化、硼氢化氧化、铬酐氧化、二甲基锌甲基化 ,共 6步反应合成了 3 (3’ 羟基丁基 )异苯并呋喃 1(3H) 酮。     

3-羟基-1-金刚烷甲基酮的合成

改进了沙格列汀中间体3-羟基-1-金刚烷甲基酮（1）的合成路线。以金刚烷甲酸（2）为起始原料,经二氯亚砜酰氯化后与N-氯代琥珀酰亚胺（NCS)反应制得3-氯-1-金刚烷甲酰氯（3）; 3依次经取代,脱羧和与碱反应合成1,其结构经¹H NMR, IR和MS(ESI)确证。采用星点设计-效应面法对1合成条件进行了优化。结果表明:在最佳反应条件[2 28 mmol, n(NCS)/n(2)/n(AIBN)=1/0.83/0.65,于65 ℃反应8 h]下,1收率70%。     

2-(3-羟基-2-吡啶基)-苯并咪唑的合成、晶体结构及光谱研究

在合成2-(3-羟基-2-吡啶基)-苯并咪唑的基础上, 利用NMR (1H, 13C, COSY, HSQC 和HMBC), MS, IR 和UV 进
行了详细表征; 通过X-ray 单晶衍射测定该化合物的晶体结构, 实验结果表明该晶体属于单斜晶系{空间群为P21/c,
a＝14.289(3) Å, b＝10.618(2) Å, c＝12.783(3) Å, β＝93.51(3)°, V＝1935.8(7) Å3, Z＝8}, 很好支持了波谱表征的结果.
2-(3-羟基-2-吡啶基)-苯并咪唑的荧光光谱表明, 该化合物在激发态下存在双质子转移现象, 密度泛函计算结果合理解
释了实验现象.     

新的吡啶基硫醚苯甲酸的原位合成及其铜配合物

在氧化铜和溴化铜存在的条件下, 4-[1,2-(2-吡啶基)亚甲硫基]-苯甲酸(L′)经原位消去反应, 形成了一个新的有机配体4-[1,2,2-(2-吡啶基)-(2-吡啶亚甲基)亚甲硫基]-苯甲酸(L), 并与铜形成配位聚合物[Cu₂(L)Br₂]_n(1){L=4-[1,2,2-(2-吡啶基)-(2-吡啶亚甲基)亚甲硫基]-苯甲酸}, 通过红外光谱、元素分析和X射线单晶衍射等手段对其结构进行了表征.     

常山酮中间体的合成工艺改进

以2-乙酰呋喃为起始原料,经扩环、甲基化、去质子化、亲核加成、缩酮化、Rh/C催化氢化及水解等反应合成了常山酮中间体--1-(3-甲氧基哌啶-2-基)丙酮,总收率40.2%,其结构经¹H NMR和ESI-MS确证。     

离子液体中脂肪酶催化拆分外消旋烯丙酮醇反应

 以离子液体为溶剂,考察了溶剂类型、水活度、温度、 pH值和共溶剂等因素对脂肪酶催化拆分外消旋烯丙酮醇(R,S)-4-羟基-3-甲基-2-(2-丙烯基)-2-环戊烯-1-酮反应的影响,并与常用于外消旋烯丙酮醇拆分的有机溶剂乙酸乙烯酯进行了比较. 结果表明,在离子液体［bmim］PF6中脂肪酶的催化性能较好,酶初始反应速率为18.48 μmol/(g·min), 半衰期为74.53 h, 高于在乙酸乙烯酯中的相应值(9.18 μmol/(g·min)和64.29 h). 但离子液体中拆分反应的转化率低于在乙酸乙烯酯中的转化率,可以通过向离子液体中补加酰基供体来提高外消旋烯丙酮醇的转化率. 两种反应介质中最佳酶反应条件均为水活度0.17, 温度40 ℃和pH=7, 但加入共溶剂后,离子液体中脂肪酶催化拆分外消旋烯丙酮醇的效率降低,而在乙酸乙烯酯中则有所提高.     

Synthesis of Some 2-(3-Alkyl/aryl-5-trifluoromethylpyrazol-1-yl)-4-(coumarin-3-yl)thiazoles as Novel Antibacterial Agents

Abstract

Herein, we describe a one-pot synthesis of some novel 2-(3-alkyl/aryl-5-trifluoromethylpyrazol-1-yl)-4-(coumarin-3-yl)thiazoles (6) involving the reaction of 3-alkyl/aryl-5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazole-1-thiocarboxamides (3) with 3-bromoacetylcoumarins (5) in the presence of sodium carbonate in ethanol. Reaction of 3 with 5 in the absence of sodium carbonate, however, resulted in the formation of 2-(3-alkyl/aryl-5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles, which were subsequently dehydrated to 6 by refluxing in ethanol in the presence of sodium carbonate. The structure of the synthesized compounds (6) was confirmed by infrared (IR), mass, ¹H NMR, and ¹³C NMR spectra and elemental analysis data. Newly synthesized compounds (6) showed moderate to good activity against Gram-positive bacteria.     

1-(3,5-二甲基苯基)-1-[(1S,4S)-1,7,7-三甲基双环[2.2.1]庚烷-2-基]肼的合成工艺改进

以3,5-二甲基苯胺和2-莰酮为起始原料,在微波促进下,经缩合反应制得N-(3,5-二甲基苯基)-1-(1S,4S)-1,7,7-三甲基二环[2.2.1]庚烷-2-亚胺(1);1经硼氢化钠还原后再与羟胺-O-磺酸经胺化反应合成了1-(3,5-二甲基苯基)-1-[(1S,4S)-1,7,7-三甲基双环[2.2.1]庚烷-2-基]肼,总收率70.4%,其结构经1H NMR和ESI-MS确证。     

Syntheses,structures, and properties of four coordination polymers based on 2,7-di(pyridin-4-yl)-9H-fluoren-9-one

Four coordination polymers (CPs), [Cd(2,7-dpfo)₂(NO₃)₂(CH₃OH)]_n (1) , [Zn(2,7-dpfo)(NO₃)(CH₃COO)]_n (2) , [Co(2,7-dpfo)₂(H₂L)]_n (3) , and [Ni(2,7-dpfo)₂(H₂L)]_n (4) (where 2,7-dpfo is 2,7-di(pyridin-4-yl)-9H-fluoren-9-one and H₄L is 1,1′:4′,1′′-terphenyl-4,2′,5′,4′′-tetracarboxylic acid), were synthesized and structurally characterized. Compounds 1 – 4 were determined by elemental analyses, single crystal X-ray diffraction analyses, powder X-ray diffraction, infrared spectroscopy, and thermogravimetric analyses. Compound 1 displays a one-dimensional (1D) zigzag chain structure, while compound 2 possesses a 1D ladder chain structure. Compounds 3 and 4 are isostructural and consist of 1D chains. The solid-state luminescent properties of 1 and 2 and the magnetic properties of 3 and 4 were also investigated.     

Synthesis of Gingerenone C and 5-Hydroxy-1-(4'-hydroxy- 3'-methoxyphenyl)-7-(4"-hydroxyphenyl)-3-heptanone

The two diarylheptanoids (E)-1-(4'-hydroxy-3'-methoxyphenyl)-7-(4"-hydroxyphenyl) hept-4-en-3-one 1 (Gingerenone C) and (±)-5-hydroxy-1-(4'-hydroxy-3'-methoxyphenyl)-7-(4"-hydroxyphenyl)-3-heptanone 2 were synthesized from vanillin 3 and 4-hydroxybenzaldehyde 9.     

Synthesis of 4-Hydroxy- and 4-Amino-2-Methyl-3-(2-Methylindol-3-Yl)methylquinolines and Their 6- and 8-Substituted Derivatives

A method has been developed for the synthesis of substituted 4-hydroxy- and 4-amino-2-methyl-3-(2-methylindol-3-yl)methylquinolines by treating the corresponding 4-hydroxy(chloro)-2-methyl-3-(3-oxobutyl)quinolines with phenylhydrazine hydrochloride. It was found that nucleophilic substitution occurred in the case of the 4-chloroquinolines together with subsequent rearrangement to give the 4-amino derivatives. The thiosemicarbazones of the corresponding 4-hydroxy-2-methyl-3-(3-oxobutyl)quinolines were also obtained.__________Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 4, pp. 554–557, April, 2005.